The British National Formulary for Children is the unrivalled guidance on prescribing, dispensing and administering medicines to children.

BNF for Children is the only child-focused drug formulary in the world that is both independent, and has rigorous, accredited content creation processes. It is trusted by health professionals worldwide as their primary source for minimising medication errors in paediatrics.

SubscribeContent Updates
Features and Benefits icon

Speed and safety: Provides rapid reference to essential information on the selection of safe and effective medicines for individual patients

Features and Benefits icon

Evidence Grading: As part of NICE accreditation recommendations, BNFc content is now evidence graded to reflect the strength of evidence behind them, increasing transparency to support healthcare professionals with clinical decision making

Features and Benefits icon

Always up-to-date: The content is revalidated, revised, and updated on a monthly basis, making sure you access only the very latest prescribing knowledge

Features and Benefits icon

Worldwide credibility: The BNFc uses clinical evidence from a diverse range of sources and a network of experts, giving you the confidence to select medicines safely

900 +

drugs

7million +

page views

200 +

treatment summaries

360

Searches per hour

Publication Updates

08 Oct
British National Formulary for Children logo
BNFC October 2019 Update

This update contains 3 significant changes.

Significant Changes: 

  • Depression– updated guidance management.
  • Rotavirus vaccine : updated guidance in-line with Public Health England recommendations.
  • Ulcerative colitis : updated guidance on management.

For further details on changes in the BNFC click on https://www.medicinescomplete.com/#/content/bnfc/PHP107699?hspl=changes

 

10 Sep
British National Formulary for Children logo
BNFC September 2019 Update

This update contains 4 significant changes, 1 dose change and 1 new preparation.

Significant Changes: 

  • Nusinersen for treating spinal muscular atrophy [NICE guidance].
  • Tocilizumab (RoActemra®): rare risk of serious liver injury including cases requiring transplantation [MHRA/CHM advice].
  • Typhoid vaccine: updated guidance in line with Public Health England recommendations.
  • Urinary-tract infections: updated guidance on management.     

Dose Changes:

  • Typhoid vaccine [booster dose added].           

New Preparations: Renoxitin® [cefoxitin].

For further details on changes in the BNFC click on https://www.medicinescomplete.com/#/content/bnfc/PHP107699?hspl=changes

 

13 Aug
British National Formulary for Children logo
BNFC August 2019 Update

This update contains 4 significant changes, 1 dose change and 1 new preparation.

Significant Changes:

  • Contraceptives, hormonal: updated guidance on combined hormonal contraceptives.
  • Crohn’s disease: updated guidance on management.
  • Flutiform® 50 microgram/ 5 microgram inhaler (fluticasone with formoterol): age range extension to include children aged 5 to 12 years for the prophylaxis of asthma.
  • Oral retinoid medicines (acitretin, isotretinoin, and tretinoin): revised and simplified pregnancy prevention educational materials for healthcare professionals and women [MHRA/CHM advice]. 

Dose Changes:

  • Epipen® preparations (adrenaline/epinephrine) [body-weight ranges for children’s dosing updated]

New Preparations: Gilenya® [fingolimod].

 

For further details on changes in the BNFC click on https://www.medicinescomplete.com/#/content/bnfc/PHP107699?hspl=changes

 

09 Jul
British National Formulary for Children logo
BNFC July 2019 Update

This update contains 1 significant changes, 2 dose changes and 2 new preparations.

Significant Changes:  

  • Magnesium sulfate: risk of skeletal adverse effects in the neonate following prolonged or repeated use in pregnancy [MHRA/CHM advice].

Dose Changes: 

  • Emicizumab [alternative dosing for existing indications added].
  • Iloprost [expression of rate of intravenous infusion updated; dosing recommendation unchanged].

New Preparations: Cuprior® [trientine dihydrochloride], Renapime® [cefepime].

 

For further details on changes in the BNFC click on https://www.medicinescomplete.com/#/content/bnfc/PHP107699?hspl=changes 

11 Jun
British National Formulary for Children logo
BNFC June 2019 Update

This update contains 11 significant changes, 2 dose changes and 2 new preparations.

Significant Changes:  

  • Elvitegravir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1 [MHRA/CHM advice] (see elvitegravir with cobicistat, emtricitabine and tenofovir alafenamide).
  • Gabapentin (Neurontin®) and risk of abuse and dependence: new scheduling requirements from 1 April [MHRA/CHM advice].
  • Immunisation schedule: updated National flu immunisation programme in-line with Public Health England recommendations.
  • Influenza vaccine: updated guidance in-line with Public Health England recommendations.
  • Malaria, prophylaxis: updated country recommendations in the Recommended regimens for prophylaxis against malaria in-line with Public Health England.
  • Malaria, prophylaxis: updated guidance in-line with Public Health England recommendations.
  • Quinolones: new MHRA/CHM advice on restrictions and precautions for use of fluoroquinolone antibiotics.
  • Renal and ureteric stones: new guidance on management.
  • Respiratory system infections, antibacterial therapy: new guidance on management of Cough, acute.
  • Valproate medicines and serious harms in pregnancy: new Annual Risk Acknowledgement Form and clinical guidance from professional bodies to support compliance with the Pregnancy Prevention Programme [MHRA/CHM advice] (see sodium valproate and valproic acid).
  • Yellow fever vaccine, live (Stamaril®) and fatal adverse reactions: extreme caution needed in people who may be immunosuppressed [MHRA/CHM advice].

Dose Changes: 

  • Caffeine citrate [maintenance dosing].
  • Malarone® Paediatric (atovaquone with proguanil hydrochloride) [update to weight ranges for prophylaxis of falciparum malaria].

New Preparations: Nucala® [mepolizumab], Slenyto ® [melatonin].

For further details on changes in the BNFC click on https://www.medicinescomplete.com/#/content/bnfc/PHP107699?hspl=changes 

14 May
British National Formulary for Children logo
BNFC May 2019 Update

This update contains 4 significant changes, 1 dose changes and 2 new preparations.

Significant Changes: 

  • Fluoroquinolone antibiotics (ciprofloxacin): new restrictions and precautions for use due to very rare reports of disabling and potentially long-lasting or irreversible side effects [MHRA/CHM advice].
  • Pneumococcal vaccine: updated guidance in-line with Public Health England recommendations.
  • Prescribing in pregnancy: medicines with teratogenic potential: what is effective contraception and how often is pregnancy testing needed? [MHRA/CHM advice].
  • Respiratory system infections, antibacterial therapy: new guidance for acute exacerbations of Bronchiectasis (non-cystic fibrosis)
    Dose Changes:
  • Glycerol phenylbutyrate [Dose rounding recommendation for children under 2 years].

New Preparations: Maviret® [glecaprevir with pibrentasvir], Symkevi® [tezacaftor with ivacaftor].

For further details on changes in the BNFC click on https://www.medicinescomplete.com/#/content/bnfc/PHP107699?hspl=changes

View more View all content updates